rAAV-Olig001-ASPA
Sponsors
Myrtelle Inc.
Conditions
Canavan DiseaseCanavan disease
Phase 1
rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease
Enrolling by invitationNCT04833907
Start: 2021-04-01End: 2027-08-31Target: 24Updated: 2025-11-14
Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of rAAVOlig001-ASPA Gene Therapy for Treatment of Children with Typical Canavan Disease
Not yet recruitingCTIS2024-519412-13-00
Target: 7Updated: 2026-02-18